Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile4 entries
2010
Illegal promotion and distribution settlement
Forest pleaded guilty to criminal charges and agreed to pay $313 million to resolve allegations involving illegal promotion of Celexa and Lexapro for unapproved pediatric depression uses, distribution of unapproved Levothroid, and obstruction-related conduct. Whistleblowers helped expose aspects of the conduct and received compensation from the settlement.
2010
Transfer-pricing criticism
Forest was criticized for transfer-pricing arrangements that legally moved some profits offshore and reduced the amount of profit recognized in the United States.
1984
Drug recall and federal investigation
A federal investigation connected to the recall of one of Forest Laboratories' drugs preceded the company's acquisition of O'Neal Jones & Feldman.
Allegations concerning Namenda generic entry
Forest Laboratories was accused of using unlawful commercial arrangements to prevent or delay generic versions of Namenda from entering the market.